MELBOURNE, AUSTRALIA and AUCKLAND, NEW ZEALAND--(Marketwire - July 21, 2008) - Living Cell Technologies Limited (ASX: LCT) (PINKSHEETS: LVCLY) today released further interim results describing clinical benefit in all patients who have received implants of DiabeCell®, the Company’s encapsulated porcine islet cells for the treatment of type 1 diabetes.
